特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

湿疹治療薬の世界市場:2020年~2024年

Eczema Therapeutics Market by Indication and Geography - Forecast and Analysis 2020-2024

発行 TechNavio (Infiniti Research Ltd.) 商品コード 920023
出版日 ページ情報 英文 152 Pages
即納可能
価格
本日の銀行送金レート: 1USD=106.59円で換算しております。
湿疹治療薬の世界市場:2020年~2024年 Eczema Therapeutics Market by Indication and Geography - Forecast and Analysis 2020-2024
出版日: 2019年12月11日 ページ情報: 英文 152 Pages
概要

世界の湿疹治療薬市場は、アトピー性皮膚炎の有病率の高さ、強力なパイプライン環境、主要製品の発売などが成長促進要因となり、予測期間中に9%以上のCAGRで拡大する見込みです。ただし、コルチコステロイドに関連する副作用、ベンダー間の激しい競争、および厳しい規制ガイドラインなどの要因が、予測期間中の湿疹治療薬業界の成長を妨げる可能性があります。

当レポートでは、世界の湿疹治療薬市場について調査分析し、市場規模および成長率、市場動向、市場促進要因・課題、市場機会について検証するほか、主要ベンダーなどについて、体系的な情報を提供しています。

目次

第1章 エグゼクティブサマリー

第2章 調査範囲

  • イントロダクション1
  • イントロダクション2
  • 米ドルの通貨換算レート

第3章 市場状況

  • 市場のエコシステム
  • 市場の特徴
  • 市場セグメンテーション分析
  • バリューチェーン分析

第4章 市場規模

  • 市場の定義
  • 市場規模(2019年)
  • 市場規模および予測(2019年~2024年)
  • 市場の見通し

第5章 ファイブフォース分析

  • バイヤーの交渉力
  • サプライヤーの交渉力
  • 新規参入の脅威
  • 代替品の脅威
  • 競争相手の脅威
  • 市況

第6章 顧客情勢

第7章 地域別情勢

  • 地域別セグメンテーション
  • 地域別比較:市場規模および予測(2019年~2024年)
  • 北米
  • 欧州
  • アジア
  • その他の地域
  • 主要国
  • 市場機会

第8章 市場セグメンテーション:症状別

  • 市場セグメンテーション:症状別
  • 症状別比較:市場規模および予測(2019年~2024年)
  • アトピー性皮膚炎
  • 接触皮膚炎
  • その他
  • 市場機会:症状別

第9章 意思決定の枠組み

第10章 成長要因と課題

  • 市場成長要因
  • 市場の課題

第11章 市場動向

  • 事業戦略
  • 地政学的不確実性
  • 医療費の増加

第12章 ベンダー情勢

  • 概要
  • 創造的破壊の状況
  • 競争シナリオ

第13章 ベンダー分析

  • 対象ベンダー
  • ベンダー分類
  • ベンダーの市場ポジショニング
  • AbbVie Inc.
  • Alliance Pharma Plc
  • Bausch Health Companies Inc.
  • Bayer AG
  • Eli Lilly and Co.
  • Encore Dermatology Inc.
  • LEO Pharma AS
  • Mylan NV
  • Pfizer Inc.
  • Sanofi

第14章 付録

  • 調査方法
  • 略語のリスト
  • ベンダーの市場ポジショニングの定義

第15章 TECHNAVIOについて

図表

LIST OF EXHIBITS:

  • Exhibit 01: Global pharmaceuticals market
  • Exhibit 02: Segments of global pharmaceuticals market
  • Exhibit 03: Market characteristics
  • Exhibit 04: Market segments
  • Exhibit 05: Vendors: Key Offerings
  • Exhibit 06: Market definition - Inclusions and exclusions checklist
  • Exhibit 07: Market size 2019
  • Exhibit 08: Global market: Size and forecast 2019-2024 ($ millions)
  • Exhibit 09: Global market: Year-over-year growth 2020-2024 (%)
  • Exhibit 10: Five forces analysis 2019
  • Exhibit 11: Five forces analysis 2024
  • Exhibit 12: Bargaining power of buyers
  • Exhibit 13: Bargaining power of suppliers
  • Exhibit 14: Threat of new entrants
  • Exhibit 15: Threat of substitutes
  • Exhibit 16: Threat of rivalry
  • Exhibit 17: Market condition - Five forces 2019
  • Exhibit 18: Customer landscape
  • Exhibit 19: Market share by geography 2019-2024 (%)
  • Exhibit 20: Geographic comparison
  • Exhibit 21: North America - Market size and forecast 2019-2024 ($ millions)
  • Exhibit 22: North America - Year-over-year growth 2020-2024 (%)
  • Exhibit 23: Top 3 countries in North America
  • Exhibit 24: Europe - Market size and forecast 2019-2024 ($ millions)
  • Exhibit 25: Europe - Year-over-year growth 2020-2024 (%)
  • Exhibit 26: Top 3 countries in Europe
  • Exhibit 27: Asia - Market size and forecast 2019-2024 ($ millions)
  • Exhibit 28: Asia - Year-over-year growth 2020-2024 (%)
  • Exhibit 29: Top 3 countries in Asia
  • Exhibit 30: ROW - Market size and forecast 2019-2024 ($ millions)
  • Exhibit 31: ROW - Year-over-year growth 2020-2024 (%)
  • Exhibit 32: Top 3 countries in ROW
  • Exhibit 33: Key leading countries
  • Exhibit 34: Market opportunity
  • Exhibit 35: Indication - Market share 2019-2024 (%)
  • Exhibit 36: Comparison by indication
  • Exhibit 37: Atopic dermatitis - Market size and forecast 2019-2024 ($ millions)
  • Exhibit 38: Atopic dermatitis - Year-over-year growth 2020-2024 (%)
  • Exhibit 39: Contact dermatitis - Market size and forecast 2019-2024 ($ millions)
  • Exhibit 40: Contact dermatitis - Year-over-year growth 2020-2024 (%)
  • Exhibit 41: Other indication - Market size and forecast 2019-2024 ($ millions)
  • Exhibit 42: Other indication - Year-over-year growth 2020-2024 (%)
  • Exhibit 43: Market opportunity by indication
  • Exhibit 44: Product launch details
  • Exhibit 45: Impact of drivers and challenges
  • Exhibit 46: Business strategies
  • Exhibit 47: Vendor landscape
  • Exhibit 48: Landscape disruption
  • Exhibit 49: Vendors covered
  • Exhibit 50: Vendor classification
  • Exhibit 51: Market positioning of vendors
  • Exhibit 52: AbbVie Inc. - Vendor overview
  • Exhibit 53: AbbVie Inc. - Business segments
  • Exhibit 54: AbbVie Inc. - Organizational developments
  • Exhibit 55: AbbVie Inc. - Geographic focus
  • Exhibit 56: AbbVie Inc. - Key offerings
  • Exhibit 57: AbbVie Inc. - Key customers
  • Exhibit 58: Alliance Pharma Plc - Vendor overview
  • Exhibit 59: Alliance Pharma Plc - Business segments
  • Exhibit 60: Alliance Pharma Plc - Organizational developments
  • Exhibit 61: Alliance Pharma Plc - Geographic focus
  • Exhibit 62: Alliance Pharma Plc - Segment focus
  • Exhibit 63: Alliance Pharma Plc - Key offerings
  • Exhibit 64: Alliance Pharma Plc - Key customers
  • Exhibit 65: Bausch Health Companies Inc. - Vendor overview
  • Exhibit 66: Bausch Health Companies Inc. - Business segments
  • Exhibit 67: Bausch Health Companies Inc. - Organizational developments
  • Exhibit 68: Bausch Health Companies Inc. - Geographic focus
  • Exhibit 69: Bausch Health Companies Inc. - Segment focus
  • Exhibit 70: Bausch Health Companies Inc. - Key offerings
  • Exhibit 71: Bausch Health Companies Inc. - Key customers
  • Exhibit 72: Bayer AG - Vendor overview
  • Exhibit 73: Bayer AG - Business segments
  • Exhibit 74: Bayer AG - Organizational developments
  • Exhibit 75: Bayer AG - Geographic focus
  • Exhibit 76: Bayer AG - Segment focus
  • Exhibit 77: Bayer AG - Key offerings
  • Exhibit 78: Bayer AG - Key customers
  • Exhibit 79: Eli Lilly and Co. - Vendor overview
  • Exhibit 80: Eli Lilly and Co. - Business segments
  • Exhibit 81: Eli Lilly and Co. - Organizational developments
  • Exhibit 82: Eli Lilly and Co. - Geographic focus
  • Exhibit 83: Eli Lilly and Co. - Segment focus
  • Exhibit 84: Eli Lilly and Co. - Key offerings
  • Exhibit 85: Eli Lilly and Co. - Key customers
  • Exhibit 86: Encore Dermatology Inc. - Vendor overview
  • Exhibit 87: Encore Dermatology Inc. - Product segments
  • Exhibit 88: Encore Dermatology Inc. - Organizational developments
  • Exhibit 89: Encore Dermatology Inc. - Key offerings
  • Exhibit 90: Encore Dermatology Inc. - Key customers
  • Exhibit 91: LEO Pharma AS - Vendor overview
  • Exhibit 92: LEO Pharma AS - Product segments
  • Exhibit 93: LEO Pharma AS - Organizational developments
  • Exhibit 94: LEO Pharma AS - Key offerings
  • Exhibit 95: LEO Pharma AS - Key customers
  • Exhibit 96: Mylan NV - Vendor overview
  • Exhibit 97: Mylan NV - Product segments
  • Exhibit 98: Mylan NV - Organizational developments
  • Exhibit 99: Mylan NV - Geographic focus
  • Exhibit 100: Mylan NV - Segment focus
  • Exhibit 101: Mylan NV - Key offerings
  • Exhibit 102: Mylan NV - Key customers
  • Exhibit 103: Pfizer Inc. - Vendor overview
  • Exhibit 104: Pfizer Inc. - Business segments
  • Exhibit 105: Pfizer Inc. - Organizational developments
  • Exhibit 106: Pfizer Inc. - Geographic focus
  • Exhibit 107: Pfizer Inc. - Segment focus
  • Exhibit 108: Pfizer Inc. - Key offerings
  • Exhibit 109: Pfizer Inc. - Key customers
  • Exhibit 110: Sanofi - Vendor overview
  • Exhibit 111: Sanofi - Business segments
  • Exhibit 112: Sanofi - Organizational developments
  • Exhibit 113: Sanofi - Geographic focus
  • Exhibit 114: Sanofi - Segment focus
  • Exhibit 115: Sanofi - Key offerings
  • Exhibit 116: Sanofi - Key customers
  • Exhibit 117: Validation techniques employed for market sizing
  • Exhibit 118: Definition of market positioning of vendors
目次
Product Code: IRTNTR40707

About this market

Technavio's eczema therapeutics market analysis considers sales from atopic dermatitis, contact dermatitis, and other indication. Our study also finds the sales of eczema therapeutics in Asia, Europe, North America, and ROW. In 2019, the atopic dermatitis segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as the high prevalence of chronic, highly pruritic inflammatory skin disorders will play a significant role in the atopic dermatitis segment to maintain its market position. Also, our global eczema therapeutics market report looks at factors such as the high prevalence of atopic dermatitis, strong pipeline landscapes, and major product launches. However, side effects associated with corticosteroids, intense competition among vendors, and stringent regulatory guidelines may hamper the growth of the eczema therapeutics industry over the forecast period.

Overview

High prevalence of atopic dermatitis

Exposure to skin irritants including soaps or cleaners and allergens such as pet dander, pollen, or peanuts can lead to eczema. It is also caused by infections, dry skin, and stress. Atopic dermatitis is one of the most prevalent forms of eczema which requires multiple visits to dermatologists and numerous medications for treatment. China, India, and Japan are the three major revenue contributors to the market as these regions of Asia constitute a huge patient pool and consequently exhibit a high demand for eczema therapeutics. Thus, the high prevalence of atopic dermatitis will lead to the expansion of the global eczema therapeutics market at a CAGR of over 9% during the forecast period.

Increasing healthcare expenditure

Healthcare expenditure is increasing owing to the growing prevalence of allergic and inflammatory skin diseases in people globally. For the treatment of highly prevalent diseases such as atopic dermatitis, dermatologists are prescribing many OTC drugs and generic medications such as corticosteroids, antihistamines, and topical antiseptics due to the high number of clinical visits. The market is also witnessing an increased adoption of expensive, novel, and branded drugs for a more effective treatment. Moreover, the growing awareness of the need for early diagnosis of skin diseases, as well as the risks of negligence in seeking timely medical help, is making people increasingly health-conscious, which, in turn, is organically increasing the healthcare expenditure.

For the detailed list of factors that will drive the global eczema therapeutics market during the forecast period 2020-2024, view our report.

Competitive Landscape

With the presence of several major players, the global eczema therapeutics market is fragmented. Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading eczema therapeutics manufacturers, that include AbbVie Inc., Alliance Pharma Plc, Bausch Health Companies Inc., Bayer AG, Eli Lilly and Co., Encore Dermatology Inc., LEO Pharma AS, Mylan NV, Pfizer Inc., and Sanofi.

Also, the eczema therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

TABLE OF CONTENTS

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

  • 2.1 Preface
  • 2.2 Preface
  • 2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis
  • Value chain analysis

PART 04: MARKET SIZING

  • Market definition
  • Market sizing 2019
  • Market size and forecast 2019-2024
  • Market outlook

PART 05: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 06: CUSTOMER LANDSCAPE

PART 07: GEOGRAPHIC LANDSCAPE

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2019-2024
  • Europe - Market size and forecast 2019-2024
  • Asia - Market size and forecast 2019-2024
  • ROW - Market size and forecast 2019-2024
  • Key leading countries
  • Market opportunity

PART 08: MARKET SEGMENTATION BY INDICATION

  • Market segmentation by indication
  • Comparison by indication
  • Atopic dermatitis - Market size and forecast 2019-2024
  • Contact dermatitis - Market size and forecast 2019-2024
  • Other indication - Market size and forecast 2019-2024
  • Market opportunity by indication

PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 11: MARKET TRENDS

  • Business strategies
  • Geopolitical uncertainties
  • Increasing healthcare expenditure

PART 12: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption
  • Competitive scenario

PART 13: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • AbbVie Inc.
  • Alliance Pharma Plc
  • Bausch Health Companies Inc.
  • Bayer AG
  • Eli Lilly and Co.
  • Encore Dermatology Inc.
  • LEO Pharma AS
  • Mylan NV
  • Pfizer Inc.
  • Sanofi

PART 14: APPENDIX

  • Research methodology
  • List of abbreviations
  • Definition of market positioning of vendors

PART 15: EXPLORE TECHNAVIO